Cargando…

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

Complement-mediated (CM) autoimmune hemolytic anemia (AIHA) is characterized by the destruction of red blood cells (RBCs) by autoantibodies that activate the classical complement pathway. These antibodies also reduce transfusion efficacy via the lysis of donor RBCs. Because C1-inhibitor (C1-INH) is...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boer, Esther C. W., Jalink, Marit, Delvasto-Nuñez, Laura, Meulenbroek, Elisabeth M., Baas, Inge, Janssen, Susanne R., Folman, Claudia C., Gelderman, Kyra A., Wouters, Diana, Engel, Marije D., de Haas, Masja, Kersten, Marie José, Jongerius, Ilse, Zeerleder, Sacha, Vos, Josephine M. I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362545/ https://www.ncbi.nlm.nih.gov/pubmed/36920779 http://dx.doi.org/10.1182/bloodadvances.2022009402

Ejemplares similares

P1530: PERITRANFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL.
por: de Boer, E. C. W., et al.
Publicado: (2022)

Anti-glycoprotein antibodies and sequestration pattern of indium-labeled platelets in immune thrombocytopenia
por: Amini, Sufia N., et al.
Publicado: (2022)

Halting targeted and collateral damage to red blood cells by the complement system
por: Jalink, M., et al.
Publicado: (2021)

Sugar Matters: Improving In Vivo Clearance Rate of Highly Glycosylated Recombinant Plasma Proteins for Therapeutic Use
por: Zeerleder, Sacha, et al.
Publicado: (2021)

Plasma Exchange Therapy Using Solvent Detergent-Treated Plasma: An Observational Pilot Study on Complement, Neutrophil and Endothelial Cell Activation in a Case Series of Patients Suffering from Atypical Hemolytic Uremic Syndrome
por: de Wit, Yasmin, et al.
Publicado: (2022)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

Reference Intervals of Factor H and Factor H-Related Proteins in Healthy Children
por: van Beek, Anna E., et al.
Publicado: (2018)

Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study
por: Schär, Deborah Tabita, et al.
Publicado: (2021)

Vascular surgery patients with elevated neutrophil-to-lymphocyte ratios have downregulated neutrophil complement RNA expression
por: Chan, Ernest R., et al.
Publicado: (2022)

Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets
por: Rijkers, Maaike, et al.
Publicado: (2019)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022)

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
por: Elsawy, Mahmoud, et al.
Publicado: (2022)

The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation
por: de Boer, Esther CW, et al.
Publicado: (2023)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant
por: Chung, David J., et al.
Publicado: (2022)

Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial
por: Hsu, Peter, et al.
Publicado: (2021)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia
por: Kreitman, Robert J., et al.
Publicado: (2023)

A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD
por: Cronin, Robert M., et al.
Publicado: (2023)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
por: Cohen, Adam D., et al.
Publicado: (2023)

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials
por: Valtis, Yannis K., et al.
Publicado: (2021)

Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
por: Stella, Federico, et al.
Publicado: (2023)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
por: Shimony, Shai, et al.
Publicado: (2023)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL
por: Feng, Qianxi, et al.
Publicado: (2022)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
por: Dickinson, Michael, et al.
Publicado: (2021)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma
por: Peres, Lauren C., et al.
Publicado: (2022)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2n87698dolt9qd882l5hhi0mdh